Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 30.
doi: 10.1111/all.70032. Online ahead of print.

Two-Year Turning Point With Dupilumab in CRSwNP: Control, Remission, and Tapering Dosage

Eugenio De Corso  1 , Claudio Montuori  1   2 , Carlotta Pipolo  3 , Ignazio La Mantia  4 , Ernesto Pasquini  5 , Angelo Ghidini  6 , Veronica Seccia  7 , Giancarlo Ottaviano  8 , Elena Cantone  9   10 , Giulia Dané  11 , Massimiliano Garzaro  12 , Gian Luca Fadda  13 , Sara Torretta  14 , Francesca Anastasi  15 , Frank Rikki Mauritz Canevari  16 , Fabio Pagella  17 , Daniela Lucidi  18 , Carlo Cavaliere  19 , Giulio Pagliuca  20 , Marianna Maffei  21 , Francesco Bussu  22   23 , Marco Corbò  1   2 , Leandro Maria D Auria  2 , Gabriele De Maio  2 , Antonella Loperfido  24 , Stefania Gallo  25   26 , Giuseppe D Agostino  2 , Diana Giannarelli  27 , Jacopo Galli  1   2 ; DUPIREAL Italian Study Group
Collaborators, Affiliations

Two-Year Turning Point With Dupilumab in CRSwNP: Control, Remission, and Tapering Dosage

Eugenio De Corso et al. Allergy. .

Abstract

Background: Dupilumab is an effective treatment for severe, uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP). Most real-life studies have been conducted on small patient cohorts for up to 1 year.

Methods: This ambispective, multicentric, 2-year-long study evaluated dupilumab effectiveness (including treatment response, disease control, and remission) and safety in severe, uncontrolled CRSwNP patients from the DUPIREAL Italian study centers.

Results: The study involved 926 patients. At 24 months, median nasal polyp score (NPS), nasal obstruction visual analogue scale (VAS), Sino-nasal Outcome Test-22 (SNOT-22), and olfaction improved from baseline (all p < 0.0001). Patients with NPS > 4, and/or SNOT-22 > 30, and/or Sniffin' Sticks Identification Test-16 (SSIT-16) < 12 at 12 months demonstrated improvements in these outcomes over the second year. Overall, 18.7% of patients extended the dupilumab interdose interval to every 4 weeks (q4w). Notably, 91.2% of patients were "good-to-excellent" responders based on EPOS/Euforea criteria. Given the absence of standardized definitions for disease control and remission, we proposed different sets of criteria reporting results from different scenarios. Remission analysis is clinically important as it helps define treatment success and long-term therapeutic goals. Most adverse events were mild-to-moderate; 2.4% of patients discontinued treatment due to safety concerns.

Conclusions: This is the largest real-life study evaluating dupilumab in CRSwNP over 2 years. Dupilumab showed sustained effectiveness, with progressive improvements across all clinical outcomes. Dupilumab tapering did not compromise outcomes; treatment continuation allowed meaningful clinical benefits in late responders. Two-year rates of disease control and remission are clinically relevant, although standardized criteria to assess these outcomes are needed.

Keywords: CRSwNP; control; dupilumab; late response; long term; remission.

PubMed Disclaimer

References

    1. T. M. Laidlaw, C. Bachert, N. Amin, et al., “Dupilumab Improves Upper and Lower Airway Disease Control in Chronic Rhinosinusitis With Nasal Polyps and Asthma,” Annals of Allergy, Asthma & Immunology 126, no. 5 (2021): 584–592.e1.
    1. C. Bachert, J. K. Han, M. Desrosiers, et al., “Efficacy and Safety of Dupilumab in Patients With Severe Chronic Rhinosinusitis With Nasal Polyps (LIBERTY NP SINUS‐24 and LIBERTY NP SINUS‐52): Results From Two Multicentre, Randomised, Double‐Blind, Placebo‐Controlled, Parallel‐Group Phase 3 Trials,” Lancet 394, no. 10209 (2019): 1638–1650.
    1. M. Desrosiers, L. P. Mannent, N. Amin, et al., “Dupilumab Reduces Systemic Corticosteroid Use and Sinonasal Surgery Rate in CRSwNP,” Rhinology 59, no. 3 (2021): 301–311.
    1. E. De Corso, S. Settimi, C. Montuori, et al., “Effectiveness of Dupilumab in the Treatment of Patients With Severe Uncontrolled CRSwNP: A “Real‐Life” Observational Study in the First Year of Treatment,” Journal of Clinical Medicine 11, no. 10 (2022): 2684.
    1. G. Ottaviano, T. Saccardo, G. Roccuzzo, et al., “Effectiveness of Dupilumab in the Treatment of Patients With Uncontrolled Severe CRSwNP: A “Real‐Life” Observational Study in Naïve and Post‐Surgical Patients,” Journal of Personalized Medicine 12, no. 9 (2022): 1526.

LinkOut - more resources